Advertisement

x

International Precision Medicine Conference

April 19-21, 2021 | Orlando, USA

Scopus Indexed Conference
scopus
Holiday Inn Orlando SW Celebration Area, 5711 W. Irlo Bronson Memorial Highway, Kissimmee, FL 34746, USA
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 (540) 709-1879
Email: precision@magnus-event.com
April 19-21, 2021 | Orlando, USA

Mohammad Ali Boroumand

International Precision Medicine Conference- Mohammad Ali Boroumand
Mohammad Ali Boroumand
Tehran Heart Center, Tehran University of Medical Sciences, Iran
Title : SENCR Long non-coding RNA in circulating endothelial cells as the early non-invasive tool for risk assessment of early-onset coronary artery disease

Abstract:

Precise and early diagnosis of coronary artery disease (CAD), especially in young and middle-aged patients could improve life-expectancy and prevent life-threatening complications. Recent advances illustrated the association between SENCR, a novel long non-coding RNA, and endothelial dysfunction (ED), as the earliest pathogenic event in atherosclerotic plaque formation. Although different methods are available for the assessment of ED in clinical practice, limited access to vascular endothelium is considered the main constraint. We hypothesized that rare and viable circulating endothelial cells (CECs) in peripheral blood, as representative of vascular endothelium, could be used as the non-invasive tool for remotely monitoring of intra-endothelial SENCR alteration during the process of endothelial dysfunction and atherosclerotic plaque formation.  

Methods: A single-cell expression study was conducted for the assessment of SENCR expression level among CECs derived from 253 young individuals (Males ≤45 and Females≤55 years old) with and without CAD. Fluorescence in situ hybridization- Flow cytometry (FISH-Flow) assay in our study, provided a precise tool for concurrent detection of CECs and quantification of intra-endothelial SENCR using specific fluorescent-labeled probe and antibodies. Fluorescence data (MFI or mean fluorescence intensity) were gathered among flow cytometry-based gated cells (CECs) representing SSClow-intermediate, CD31Bright, CD45Neg, and CD146+. SENCR expression data were compared between the subjects after categorizing into quartile groups based on CAD severity and Gensini score (very low, low, medium and high).

Results: Our results showed that our subjects without or with minimal angiographically evidence of stenosis (Gensini score ≤2.5; very low quartile) had the highest expression level of SENCR in their CECs. Young patients with Gensini score between 3.0 and 26.0 (Low quartile) showed remarkably decrease in intra-endothelial SENCR level compared to very low level group (P=0.021). Although decreasing of SENCR repeated through two other groups (medium and high quartiles), intra-endothelial SENCR level among our patients could not predict the disease state (Low, medium and high level of Gensini score) (p=0.306).  

Conclusions: SENCR alteration in viable CECs could reflect the contribution of vascular endothelium to the process of ED and atherosclerotic plaque formation but not atherosclerosis progression. This non-invasive epigenetic biomarker might be benefit in risk stratification and therapeutic decision making in youth at risk of atherosclerosis development.

Audience Take Away:

  • Misdiagnosis or delay in the diagnosis of coronary artery disease in most of the patients could lead to invasive coronary procedure and higher treatment costs. We tried to present a biomarker which might be useful for the early diagnosis of atherosclerosis development.
  • The presented novel approach for remotely vascular endothelium analysis using FISH-Flow technology, may provide a non-invasive accessible tool for researchers who focus on vascular biology and also for physicians to help in early diagnosis and decision-making in clinical practice.
  • Our findings may help to provide a new insight to develop the models for risk assessment and diagnosis of subclinical atherosclerosis among young individuals.

Biography:

Dr. Boroumand studied medicine at the Isfahan University of Medical Sciences, Iran in 1995 and after four-year residency program graduated as pathologist at the Tehran University of Medical Sciences in 1999. He then joined the Tehran Heart Center (THC) as the head of pathology and laboratory medicine department and a member of cardiovascular research council in 2002. He obtained the position of a Professor at the Tehran University of Medical Sciences in 2014. He had some multicenter collaborative studies in Iran and Italy (Fondazion Luigi Villa, Milan, Italy). He has published more than 130 research articles in SCI journals.

Watsapp